Biosyngen

Focus: Biosyngen is a Singapore-based biotechnology company founded in 2023 focused on cell & gene therapy and antibodies, currently in early-stage clinical development with a pipeline concentrated in oncology indications.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Biosyngen

AI assessmentNot Hiring

No open roles listed right now. Follow Biosyngen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Single drug group A

Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT06643910A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer

N/A

Help build intelligence for Biosyngen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded biotech with early-stage gene therapy and CAR-T programs spanning multiple high-value cancer indications
Exposure to cutting-edge cell & gene therapy modalities across 8 active clinical programs including hepatocellular carcinoma, nasopharyngeal carcinoma, and liver cancer
Singapore headquarters provides unique Asia-Pacific market positioning and regulatory pathway access

Watch Out For

Company founded in 2023 with no disclosed funding, revenue, or employee count raises questions about financial runway and organizational maturity
All 8 pipeline programs remain in Phase 1/early Phase 2 with no Phase 3 programs or marketed products, meaning 5+ years minimum before any commercial validation
No active job openings and minimal public disclosure create uncertainty about hiring capacity and company stability

Generated by Claude from Biosyngen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BST02 Injection

Locally Advanced/Metastatic Liver Cancer

Phase 1

Clinical Trials (1)

NCT06173726Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer

Phase 1

Group A

Colorectal Cancer

Phase 1

Clinical Trials (1)

NCT06645301BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies

Phase 1

Group A

Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT06645314Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma

Phase 1

First dose

Gastrointestinal Tumors

Phase 1

Clinical Trials (1)

NCT06152757BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

Phase 1

Cohort A: 3.0x10^6 CAR-T cells/kg

EBV-positive Nasopharyngeal Carcinoma

Phase 1

Clinical Trials (1)

NCT05864924A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

Phase 1

BST02

Locally Advanced Liver Carcinoma

Phase 1

Clinical Trials (1)

NCT06526832A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer

Phase 1

BSG-001

Malignant Pleural Effusion

Phase 1/2

Clinical Trials (1)

NCT03736122A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 8 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

7 pipeline

Marketed

Pipeline